Newsroom

Two months after the approval of the first biosimilar to infliximab, another Biologics License Application is now under FDA review.
The smallest overall increase in the MMI in 15 years is masked by the fact that employees are bearing an increasingly large share of healthcare costs.
A recent study showed patients with type 2 diabetes did better if given the combination therapy at the outset than if given 1 of the components as monotherapy.
California’s approach to the healthcare marketplace, Covered California, has successfully held down premium costs because it has authority to select health insurers.
A survey conducted by MaPS/Millward Brown Analytics, on behalf of Memorial Sloan Kettering Cancer Center, has identified multiple concerns of American consumers with cancer clinical trial participation, which could be responsible for the dismal 4% national enrollment rate in clinical trials.
What we're reading, May 24, 2016: Doubt grows about the stability of the Anthem-Cigna merger; use of e-cigarettes and vaping devices stalls in the US; and drugmakers are cautious about developing a Zika virus.
A phase 1 study in 225 patients diagnosed with breast cancer, non-small cell lung cancer, glioblastoma, melanoma, or colorectal cancer has concluded that abemaciclib, a selective inhibitor of the cell cycle regulators CDK4/6, has single-agent activity in specific tumor types.
For patients with private drug insurance plans, out-of-pocket expenses, not the timing of patient reimbursements, have a greater affect on medication adherence.
Compendia
Diabetes Compendium
Oncology Compendium
Reimbursement Compendium
HF Compendium
$AD300x250BB$
$vacMongoViewPlus$